HIV–HBV and HIV–HCV coinfection and liver cancer development

Jianming Hu, Kuancheng Liu, Jun Luo

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Liver diseases that are caused by the hepatitis B virus (HBV) and hepatitis C virus (HCV), including cirrhosis and hepatocellular carcinoma (HCC), have become increasingly important in patients infected with the human immunodeficiency virus (HIV) as their life expectancy is getting longer with successful anti-HIV therapy. Due to their shared transmission routes, dual infection by HIV and HBV or HIV and HCV, and triple infection by all three viruses are fairly common and affect millions of people worldwide. Whereas the immunodeficiency caused by HIV enhances the likelihood of HBV and HCV persistence, hepatotoxicity associated with anti-HIV therapy can worsen the liver diseases associated with HBV or HCV persistence. Evidence suggests HIV infection increases the risk of HBV- or HCV-associated HCC risk although the precise mechanisms of enhanced hepatocarcinogenesis remain to be fully elucidated. Recent success in curing HCV infection, and the availability of therapeutic options effective in long-term suppression of both HIV and HBV replication, bring hope, fortunately, to those who are coinfected but also highlight the need for judicious selection of antiviral therapies.

Original languageEnglish (US)
Title of host publicationCancer Treatment and Research
PublisherSpringer International Publishing
Pages231-250
Number of pages20
DOIs
StatePublished - Jan 1 2019

Publication series

NameCancer Treatment and Research
Volume177
ISSN (Print)0927-3042

Fingerprint

Liver Neoplasms
Coinfection
Hepatitis B virus
HIV
Hepacivirus
Virus Diseases
Liver Diseases
Hepatocellular Carcinoma
Therapeutics
Virus Replication
Life Expectancy
Antiviral Agents
Fibrosis
Viruses
Infection

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Hu, J., Liu, K., & Luo, J. (2019). HIV–HBV and HIV–HCV coinfection and liver cancer development. In Cancer Treatment and Research (pp. 231-250). (Cancer Treatment and Research; Vol. 177). Springer International Publishing. https://doi.org/10.1007/978-3-030-03502-0_9
Hu, Jianming ; Liu, Kuancheng ; Luo, Jun. / HIV–HBV and HIV–HCV coinfection and liver cancer development. Cancer Treatment and Research. Springer International Publishing, 2019. pp. 231-250 (Cancer Treatment and Research).
@inbook{5fb58b8e81f440b3a8a7f033add5e986,
title = "HIV–HBV and HIV–HCV coinfection and liver cancer development",
abstract = "Liver diseases that are caused by the hepatitis B virus (HBV) and hepatitis C virus (HCV), including cirrhosis and hepatocellular carcinoma (HCC), have become increasingly important in patients infected with the human immunodeficiency virus (HIV) as their life expectancy is getting longer with successful anti-HIV therapy. Due to their shared transmission routes, dual infection by HIV and HBV or HIV and HCV, and triple infection by all three viruses are fairly common and affect millions of people worldwide. Whereas the immunodeficiency caused by HIV enhances the likelihood of HBV and HCV persistence, hepatotoxicity associated with anti-HIV therapy can worsen the liver diseases associated with HBV or HCV persistence. Evidence suggests HIV infection increases the risk of HBV- or HCV-associated HCC risk although the precise mechanisms of enhanced hepatocarcinogenesis remain to be fully elucidated. Recent success in curing HCV infection, and the availability of therapeutic options effective in long-term suppression of both HIV and HBV replication, bring hope, fortunately, to those who are coinfected but also highlight the need for judicious selection of antiviral therapies.",
author = "Jianming Hu and Kuancheng Liu and Jun Luo",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/978-3-030-03502-0_9",
language = "English (US)",
series = "Cancer Treatment and Research",
publisher = "Springer International Publishing",
pages = "231--250",
booktitle = "Cancer Treatment and Research",

}

Hu, J, Liu, K & Luo, J 2019, HIV–HBV and HIV–HCV coinfection and liver cancer development. in Cancer Treatment and Research. Cancer Treatment and Research, vol. 177, Springer International Publishing, pp. 231-250. https://doi.org/10.1007/978-3-030-03502-0_9

HIV–HBV and HIV–HCV coinfection and liver cancer development. / Hu, Jianming; Liu, Kuancheng; Luo, Jun.

Cancer Treatment and Research. Springer International Publishing, 2019. p. 231-250 (Cancer Treatment and Research; Vol. 177).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - HIV–HBV and HIV–HCV coinfection and liver cancer development

AU - Hu, Jianming

AU - Liu, Kuancheng

AU - Luo, Jun

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Liver diseases that are caused by the hepatitis B virus (HBV) and hepatitis C virus (HCV), including cirrhosis and hepatocellular carcinoma (HCC), have become increasingly important in patients infected with the human immunodeficiency virus (HIV) as their life expectancy is getting longer with successful anti-HIV therapy. Due to their shared transmission routes, dual infection by HIV and HBV or HIV and HCV, and triple infection by all three viruses are fairly common and affect millions of people worldwide. Whereas the immunodeficiency caused by HIV enhances the likelihood of HBV and HCV persistence, hepatotoxicity associated with anti-HIV therapy can worsen the liver diseases associated with HBV or HCV persistence. Evidence suggests HIV infection increases the risk of HBV- or HCV-associated HCC risk although the precise mechanisms of enhanced hepatocarcinogenesis remain to be fully elucidated. Recent success in curing HCV infection, and the availability of therapeutic options effective in long-term suppression of both HIV and HBV replication, bring hope, fortunately, to those who are coinfected but also highlight the need for judicious selection of antiviral therapies.

AB - Liver diseases that are caused by the hepatitis B virus (HBV) and hepatitis C virus (HCV), including cirrhosis and hepatocellular carcinoma (HCC), have become increasingly important in patients infected with the human immunodeficiency virus (HIV) as their life expectancy is getting longer with successful anti-HIV therapy. Due to their shared transmission routes, dual infection by HIV and HBV or HIV and HCV, and triple infection by all three viruses are fairly common and affect millions of people worldwide. Whereas the immunodeficiency caused by HIV enhances the likelihood of HBV and HCV persistence, hepatotoxicity associated with anti-HIV therapy can worsen the liver diseases associated with HBV or HCV persistence. Evidence suggests HIV infection increases the risk of HBV- or HCV-associated HCC risk although the precise mechanisms of enhanced hepatocarcinogenesis remain to be fully elucidated. Recent success in curing HCV infection, and the availability of therapeutic options effective in long-term suppression of both HIV and HBV replication, bring hope, fortunately, to those who are coinfected but also highlight the need for judicious selection of antiviral therapies.

UR - http://www.scopus.com/inward/record.url?scp=85058597524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058597524&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-03502-0_9

DO - 10.1007/978-3-030-03502-0_9

M3 - Chapter

C2 - 30523627

AN - SCOPUS:85058597524

T3 - Cancer Treatment and Research

SP - 231

EP - 250

BT - Cancer Treatment and Research

PB - Springer International Publishing

ER -

Hu J, Liu K, Luo J. HIV–HBV and HIV–HCV coinfection and liver cancer development. In Cancer Treatment and Research. Springer International Publishing. 2019. p. 231-250. (Cancer Treatment and Research). https://doi.org/10.1007/978-3-030-03502-0_9